Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Even Small Viral Load Reduction Is Beneficial for People with Highly Resistant HIV

Antiretroviral therapy (ART) can help raise CD4 T-cell counts even if it does not produce undetectable HIV RNA due to extensive drug resistance, indicating that treatment likely has immunological benefits even for people with few therapeutic options, according to a report in the March 1, 2013 Journal of Infectious Diseases.

alt

Read more:

Atazanavir (Reyataz) Label Update Adds Kidney Warning, Drug Interactions

Product label information for the HIV protease inhibitor atazanavir (brand name Reyataz) was recently revised to include new warnings about cholelithiasis or gall bladder stones and interstitial nephritis (a type of kidney inflammation), as well as interactions with several other medications, including the hepatitis C virus protease inhibitor boceprevir (Victrelis).

alt

Read more:

New HIV NNRTI Lersivirine Matches Efavirenz in Phase 2b Trial

The investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) lersivirine suppressed HIV viral load as well as efavirenz (Sustiva) in a 48-week trial, but with a different and side effect profile, researchers reported in the February 1, 2013, Journal of Acquired Immune Deficiency Syndromes.

alt

Read more:

ViiV Announces Halt to Lersivirine Development

On February 5, 2013, ViiV Healthcare announced that the company has decided to stop the development program investigating its experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) lersivirine.

alt

Read more:

Gilead Starts Phase 3 Trials for New HIV Pro-drug Tenofovir Alafenamide

Gilead Sciences announced last week that its new single-tablet regimen containing tenofovir alafenamide fumarate  (TAF) -- a pro-drug of the widely used tenofovir disoproxil fumarate (TDF) -- has entered the final phase of pre-approval clinical testing.

alt

Read more:

Only 1 in 5 Medicaid Users Linked to Care Within a Year After HIV Diagnosis

Only about 20% of adult Medicaid recipients who tested positive for HIV during the past decade began receiving appropriate care -- including CDC T-cell count and viral load monitoring -- within a year of diagnosis, and the rate did not improve much within 5 years, according to an analysis described in the January 2013 issue of Sexually Transmitted Diseases.

alt

Read more:

Complera Label Adds Low Viral Load Restriction, Liver Toxicity Warning

The U.S. Food and Drug Administration (FDA) last week approved revised label information for Complera, Gilead Sciences' tenofovir/emtricitabine/rilpivirine single-tablet regimen. Among the changes, the updated label clarifies that this regimen is indicated for previously untreated people with low baseline viral load, as those with higher levels were more likely to experience treatment failure in clinical trials.

alt

Read more: